Multiple Sclerosis, Relapsing-Remitting: all 615 studies
Page 4 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple SclerosisCompletedNCT05080270Early Phase 1
- Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in SwedenCompletedNCT05029206
- Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving CladribineStatus unknownNCT05019248
- Efficacy of Diet on Quality of Life in Multiple SclerosisActive, not recruitingNCT05007483Not applicable
- Sensitivity of Motor Assessment in MS - a Prospective Cohort StudyStatus unknownNCT04993274
- Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple SclerosisCompletedNCT04979650Phase 2
- Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialTerminatedNCT04971005Phase 2
- Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenCompletedNCT04940065
- Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl FumarateWithdrawnNCT04925778
- Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple SclerosisWithdrawnNCT04880577Phase 2
- MS Relapses During COVID-19 PandemicCompletedNCT04858763
- Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple SclerosisStatus unknownNCT04857489
- The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized TrialCompletedNCT04833673Not applicable
- Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsCompletedNCT04832399
- Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraCompletedNCT04756687
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
- Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculographyCompletedNCT04705610Not applicable
- Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisActive, not recruitingNCT04688788Phase 3
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support ProgramCompletedNCT04655222
- RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II TrialTerminatedNCT04625153Phase 2
- Real World Effectiveness of Natalizumab Extended Interval Dosing in a French CohortCompletedNCT04580381
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseActive, not recruitingNCT04578639Phase 3
- Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple SclerosisCompletedNCT04567264Not applicable
- Examining Effects of Tysabri on Cognitive Fatigue Using fMRICompletedNCT04565431
- 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple SclerosisCompletedNCT04546698
- Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple SclerosisActive, not recruitingNCT04530318Phase 2
- Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple SclerosisCompletedNCT04528121Not applicable
- Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA RegionCompletedNCT04468165
- Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple SclerosisStatus unknownNCT04450030
- Examining Effects of Ocrevus on Cognitive Fatigue Using fMRICompletedNCT04448977
- Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple SclerosisStatus unknownNCT04380220
- Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)CompletedNCT04289909Not applicable
- Acute Intermittent Hypoxia in Persons With Multiple SclerosisCompletedNCT04280484Not applicable
- tDCS to Enhance Cognitive Training in Multiple SclerosisWithdrawnNCT04261556Not applicable
- Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).Status unknownNCT04260711Not applicable
- Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple SclerosisCompletedNCT04233970Not applicable
- Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple SclerosisStatus unknownNCT04225312Phase 4
- Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPCompletedNCT04221191
- Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple SclerosisCompletedNCT04220814Not applicable
- Phase II Clinical Trial of OCH-NCNP1CompletedNCT04211740Phase 2
- Serum Neurofilaments and GFAP in Atypical Multiple SclerosisCompletedNCT04201470Not applicable
- Role of Simvastatin in Relapsing-Remitting Multiple SclerosisStatus unknownNCT04178980Phase 1
- Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated ComorbiditiesStatus unknownNCT04157283
- To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.Status unknownNCT04121637Not applicable
- Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS PatientsCompletedNCT04115930
- Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple SclerosisStatus unknownNCT04073940Not applicable
- A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of NatalizumabStatus unknownNCT04048577Phase 4
- Calorie Restriction in Multiple SclerosisActive, not recruitingNCT04042415Not applicable
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in DiseaseSuspendedNCT04031469
- Clinically Isolated Syndrome and Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04009005Not applicable
- Bazedoxifene Acetate as a Remyelinating Agent in Multiple SclerosisCompletedNCT04002934Phase 2
- RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MSActive, not recruitingNCT03979456Phase 3
- Fecal Microbiota Transplantation (FMT) in Multiple SclerosisCompletedNCT03975413
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT03958877Phase 3
- PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.CompletedNCT03942952
- Understanding Magnetic Resonance Imaging in Multiple SclerosisCompletedNCT03872583Not applicable
- PET with [18F]Flumazenil As an Index of Neurodegeneration in MSCompletedNCT03825601Not applicable
- Cognition and MRI Markers in MS Patients With Aubagio® TreatmentCompletedNCT03768648Not applicable
- Behavior Cognitive Therapy on Fatigue Impact in MS PatientsCompletedNCT03758820Not applicable
- Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MSCompletedNCT03718247
- The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple SclerosisCompletedNCT03718026
- Photobiomodulation Therapy in Persons With Multiple SclerosisCompletedNCT03691766Not applicable
- Effects Aquatic Exercises on Balance and Hand Function in Multiple SclerosisCompletedNCT03679806Not applicable
- Cortical Lesions in Patients With Multiple SclerosisCompletedNCT03653585
- Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis PatientsStatus unknownNCT03610139Not applicable
- Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)CompletedNCT03561402
- Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT03551275Phase 1
- Intermittent Fasting in Multiple SclerosisCompletedNCT03539094Not applicable
- Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple SclerosisTerminatedNCT03536559Phase 2
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingNCT03535298Phase 4
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis TrialCompletedNCT03500328Not applicable
- Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple SclerosisCompletedNCT03497468Not applicable
- Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation ProgrammeCompletedNCT03471338Not applicable
- Mechanistic Studies of Teriflunomide in RRMSCompletedNCT03464448
- Impact of Vitamin D Supplementation in Patients With Multiple SclerosisCompletedNCT03385356Phase 4
- An Extension of the TG1101-RMS201 TrialCompletedNCT03381170Phase 2
- A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisCompletedNCT03347370
- Fingolimod Versus Dimethyl-fumarate in Multiple SclerosisTerminatedNCT03345940Phase 4
- Comparison of Oral Molecules Preventing Relapses in Multiple SclerosisCompletedNCT03302442
- Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesCompletedNCT03284970
- A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMSTerminatedNCT03283397Phase 3
- Behavior and Activity Monitoring in MSCompletedNCT03244696Not applicable
- Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple SclerosisTerminatedNCT03239860Phase 2
- Clinical Decision Support System (CADIMS) for MS DiagnosticCompletedNCT03205280
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
- Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With PlegridyCompletedNCT03091569Phase 4
- Clinical Importance of Glucose Regulation in Relapsing MSStatus unknownNCT03004079
- Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple SclerosisCompletedNCT03000647Not applicable
- Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue StudyCompletedNCT02914964Not applicable
- Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarateTerminatedNCT02901106Phase 4
- Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.TerminatedNCT02833714
- Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®CompletedNCT02823951
- Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MSCompletedNCT02782858Phase 2
- Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT02776072
- Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.Status unknownNCT02769767
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT02753088Phase 3
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.CompletedNCT02746744Phase 3
- Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple SclerosisCompletedNCT02744222Phase 2/3
- High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis PatientsCompletedNCT02696590Not applicable
- TMP001 in Relapsing-remitting Multiple SclerosisCompletedNCT02686788Phase 2